Omnicell (NASDAQ:OMCL) Releases Q4 Earnings Guidance

Omnicell (NASDAQ:OMCL) issued an update on its fourth quarter earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $0.55-$0.62 for the period, compared to the consensus estimate of $0.47. The company issued revenue guidance of $295-$305 million, compared to the consensus revenue estimate of $287.85 million. Omnicell also updated its FY 2024 guidance to 1.650-1.720 EPS.

Omnicell Stock Performance

NASDAQ:OMCL traded up $0.03 during midday trading on Friday, reaching $48.67. The stock had a trading volume of 683,792 shares, compared to its average volume of 528,146. Omnicell has a 1-year low of $25.12 and a 1-year high of $55.74. The firm’s fifty day simple moving average is $43.34 and its 200-day simple moving average is $35.32. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.05 and a quick ratio of 2.22. The stock has a market capitalization of $2.24 billion, a P/E ratio of -124.79, a PEG ratio of 58.48 and a beta of 0.83.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.37. Omnicell had a negative net margin of 1.66% and a positive return on equity of 2.55%. The business had revenue of $276.80 million for the quarter, compared to analyst estimates of $254.41 million. During the same period last year, the business posted $0.29 EPS. Omnicell’s revenue was down 7.4% compared to the same quarter last year. On average, equities research analysts forecast that Omnicell will post 0.64 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

OMCL has been the topic of a number of research analyst reports. Wells Fargo & Company raised their target price on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research note on Monday, October 14th. Barclays raised their target price on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday. Craig Hallum raised their target price on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday. StockNews.com raised shares of Omnicell from a “hold” rating to a “buy” rating in a report on Saturday, October 19th. Finally, Benchmark reissued a “buy” rating and issued a $48.00 price target on shares of Omnicell in a report on Wednesday, October 9th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Omnicell presently has an average rating of “Hold” and an average target price of $49.14.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.